KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Receivables: 2013-2024

Historic Change in Receivables for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Dec 2024 value amounting to $11.1 million.

  • Rigel Pharmaceuticals' Change in Receivables rose 260.14% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 118.38%. This contributed to the annual value of $11.1 million for FY2024, which is 213.25% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Change in Receivables stood at $11.1 million for FY2024, which was up 213.25% from -$9.8 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Change in Receivables high stood at $24.8 million for FY2022, and its period low was -$9.8 million during FY2023.
  • Moreover, its 3-year median value for Change in Receivables was $11.1 million (2024), whereas its average is $8.7 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 5,059.68% in 2022, then tumbled by 139.32% in 2023.
  • Rigel Pharmaceuticals' Change in Receivables (Yearly) stood at $5.9 million in 2020, then plummeted by 108.55% to -$501,000 in 2021, then spiked by 5,059.68% to $24.8 million in 2022, then crashed by 139.32% to -$9.8 million in 2023, then surged by 213.25% to $11.1 million in 2024.